Saxenda (Liraglutide) Safety and Effectiveness in Real-World Korean Patients
A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.
Background
Global health faces a significant challenge from obesity and overweight conditions, frequently compounded by severe obesity-related comorbidities such as type 2 diabetes and cardiovascular disease. While Liraglutide 3.0 mg (Saxenda®), a GLP-1 receptor agonist (a class of drugs that mimic a natural hormone to regulate blood sugar and appetite), has demonstrated efficacy and safety in controlled clinical trials for weight management, there remains a critical need for data reflecting its performance in routine clinical practice. This study specifically addresses the knowledge gap regarding the real-world safety and effectiveness of Liraglutide 3.0 mg in a diverse Korean patient population under typical clinical conditions.
Study Design
Population
Korean patients with obesity and overweight conditions, often compounded by obesity-related comorbidities such as type 2 diabetes and cardiovascular disease.
Intervention
Liraglutide 3.0 mg (Saxenda®), a GLP-1 receptor agonist, administered for weight management.
Outcome
Real-world safety and effectiveness of Liraglutide 3.0 mg.